T. Rowe Price Associates’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q1 | – | Sell |
-901
| Closed | -$19K | – | 2971 |
|
2023
Q4 | $19K | Buy |
901
+112
| +14% | +$2.36K | ﹤0.01% | 2874 |
|
2023
Q3 | $26K | Sell |
789
-727
| -48% | -$24K | ﹤0.01% | 2834 |
|
2023
Q2 | $51K | Buy |
1,516
+789
| +109% | +$26.5K | ﹤0.01% | 2796 |
|
2023
Q1 | $31K | Hold |
727
| – | – | ﹤0.01% | 2828 |
|
2022
Q4 | $25K | Hold |
727
| – | – | ﹤0.01% | 2867 |
|
2022
Q3 | $36K | Hold |
727
| – | – | ﹤0.01% | 2867 |
|
2022
Q2 | $29K | Buy |
727
+149
| +26% | +$5.94K | ﹤0.01% | 2904 |
|
2022
Q1 | $21K | Buy |
578
+113
| +24% | +$4.11K | ﹤0.01% | 2948 |
|
2021
Q4 | $45K | Sell |
465
-47
| -9% | -$4.55K | ﹤0.01% | 2926 |
|
2021
Q3 | $64K | Buy |
512
+25
| +5% | +$3.13K | ﹤0.01% | 2887 |
|
2021
Q2 | $61K | Buy |
+487
| New | +$61K | ﹤0.01% | 2881 |
|
2020
Q1 | – | Sell |
-2,713
| Closed | -$194K | – | 2551 |
|
2019
Q4 | $194K | Sell |
2,713
-762
| -22% | -$54.5K | ﹤0.01% | 2403 |
|
2019
Q3 | $182K | Sell |
3,475
-2,721
| -44% | -$143K | ﹤0.01% | 2389 |
|
2019
Q2 | $333K | Sell |
6,196
-27
| -0.4% | -$1.45K | ﹤0.01% | 2265 |
|
2019
Q1 | $442K | Sell |
6,223
-1,773
| -22% | -$126K | ﹤0.01% | 2159 |
|
2018
Q4 | $638K | Buy |
7,996
+30
| +0.4% | +$2.39K | ﹤0.01% | 1983 |
|
2018
Q3 | $3.72M | Buy |
7,966
+11
| +0.1% | +$5.13K | ﹤0.01% | 1489 |
|
2018
Q2 | $3.16M | Buy |
7,955
+7
| +0.1% | +$2.78K | ﹤0.01% | 1498 |
|
2018
Q1 | $2.43M | Buy |
7,948
+1
| +0% | +$306 | ﹤0.01% | 1526 |
|
2017
Q4 | $2.34M | Buy |
7,947
+3
| +0% | +$883 | ﹤0.01% | 1529 |
|
2017
Q3 | $4.35M | Hold |
7,944
| – | – | ﹤0.01% | 1441 |
|
2017
Q2 | $4.73M | Buy |
7,944
+2,864
| +56% | +$1.71M | ﹤0.01% | 1419 |
|
2017
Q1 | $2.18M | Sell |
5,080
-3,200
| -39% | -$1.37M | ﹤0.01% | 1558 |
|
2016
Q4 | $4.26M | Buy |
+8,280
| New | +$4.26M | ﹤0.01% | 1436 |
|